Tislelizumab and S-1 for recurrent high-risk bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove bile duct cancer, but it came back or had high-risk signs like positive margins, multiple tumors, or spread to lymph nodes.
- You have not had chemotherapy, radiation, or other cancer treatments in the last 3 months.
- Your liver and kidney function are good enough (based on blood tests).
- You do not have other active cancers or autoimmune diseases.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.